Keqian Biology (688526): Demand pressure is dragging down performance and is expected to take the lead in benefiting from rising pig prices
Ke Qian Biology (688526): Downstream sluggish performance is temporarily under pressure, research reserves are abundant, and growth can be expected
Keqian Biology (688526) First Coverage Report: Product Strength+R&D Strength Building Core Competitiveness of Leading Companies Without Forced Exemption of Pig Seedlings
Ke Qian Biology (688526): Year-on-year decline in profit, waiting for post-cycle sentiment to recover
Southwest Securities released a research report on April 11 stating that it gave Keqian Biology (688526.SH) a purchase rating. The main reasons for the rating include: 1) comments: pig vaccines drive revenue growth, and depreciation affects profits; 2) pr
SDIC Securities released a research report on April 9 stating that it gave Keqian Biotech (688526.SH) a purchase rating. The main reasons for the rating include: 1) performance overview: Q4 performance is under pressure, and credit impairment is dragging
Keqian Biology (688526): Swine vaccine drives revenue growth, increases impairment and affects profits
Keqian Biotech (688526) 2023 Report Review: Credit impairment dragged down Q4's net profit to mother decreased by about 70% year-on-year
Guoxin Securities released a research report on April 8 stating that it gave Keqian Biology (688526.SH) a purchase rating. The main reasons for the rating include: 1) gross margin of pig vaccines is under pressure, and the pet vaccine business volume is i
Keqian Biology (688526): Depreciation drags down performance, focus on the new product launch process
Keqian Biotech (688526) 2023 Report Review: Steady operation of core single products, depreciation in the fourth quarter dragged down performance, waiting for the cycle to reverse
Keqian Biology (688526) Company Information Update Report: The implementation of various new products will immediately benefit pig cycle reversal and promotion of anti-plague vaccines
Keqian Biology (688526) 2023 Annual Report Review: Depreciation Drags Down Performance, R&D Innovation Entering the Harvest Period
Keqian Biology (688526): Q4 sales decline+depreciated profit decline year-on-year
Keqian Biology (688526): Credit impairment is dragging down profits, waiting for an inflection point in performance
Keqian Biology (688526): Increased revenue and profit, continued promotion of new products linked to production and research
Pre-clinical Biology (688526): Research and development forges competitive barriers and opens up room for growth
Commentary on the Third Quarterly Report of Keqian Biology (688526): Vaccine for pigs, stabilizes, passes emergency evaluation for good cats
Keqian Biology (688526): Credit impairment slightly dragged down performance, Q3 net profit decreased year-on-year
Keqian Biology (688526): Industry-Research Linkage Company Continues to Promote Major New Products
No Data